Mitsunori Morita

Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study

Daichi Fujimoto, Hiroshige Yoshioka, Yuki Kataoka et al. · Lung Cancer · 2018 · 150 citations

Medicine, Oncology, Pharmacology +11

Pseudoprogression in Previously Treated Patients with Non–Small Cell Lung Cancer Who Received Nivolumab Monotherapy

Daichi Fujimoto, Hiroshige Yoshioka, Yuki Kataoka et al. · Journal of Thoracic Oncology · 2018 · 121 citations

Medicine, Oncology, Pharmacotherapy +8

Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial

Daichi Fujimoto, Makiko Yomota, Akimasa Sekine et al. · Lung Cancer · 2019 · 91 citations

Medicine, Oncology, Pharmacotherapy +13

Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status

Satoshi Ikeda, Hiroshige Yoshioka, Satoshi Ikeo et al. · BMC Cancer · 2017 · 63 citations · Full text

Medicine, Geriatric Medicine, Oncology +17

Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study

Hayato Kawachi, Motohiro Tamiya, Akihiro Tamiya et al. · Investigational New Drugs · 2019 · 54 citations

Medicine, Oncology, Pharmacology +17